FDA Warns Rheumatoid Arthritis Drug Linked To Blood Clots & Pulmonary Embolism
The FDA is alerting the public that a safety clinical trial found an increased risk of blood clots in the lungs, pulmonary embolism and death when a 10 mg twice daily dose of tofacitinib (sold under the brand name Xeljanz and Xeljanz XR) was used in patients with rheumatoid arthritis. The agency stated “the FDA has not approved this 10 mg twice daily dose for rheumatoid arthritis; this dose is only approved for patients with ulcerative colitis.”
What is Xeljanz?
Xeljanz (tofacitinib) is manufactured by Pfizer and was approved by the FDA for the treatment of moderate to severe rheumatoid arthritis (RA), particularly in patients that do not respond well to other forms of treatment. The drug works by blocking the enzymes responsible for the joint inflammation that RA patients suffer.
Xeljanz Possible Injuries & Side Effects
Patients taking Xeljanz should be aware of the symptoms of a blood clot or pulmonary embolism. Please seek medical attention immediately if you experience any of the following symptoms:
- difficulty breathing
- chest pain
- pain in upper back
- coughing up blood
- excessive sweating
- bluish skin